Checkpoint inhibitors, obinutuzumab plus PET ‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘ FLUORO’ study

Documenti analoghi

• Learnings from phosphatidylinositol 3‐kinase inhibitors in lymphoma—Moving to a model where less can be more
  di: Arina Martynchyk, et al.
  Pubblicazione: (2024)
• The value of semiquantitative PET features and end‐of‐therapy PET in grade 3B follicular lymphoma
  di: Allison Barraclough, et al.
  Pubblicazione: (2024)
• Development of psoriasis during obinutuzumab treatment in a patient with follicular lymphoma
  di: Daisuke Watabe, et al.
  Pubblicazione: (2024)
• T‐Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B‐Cell Lymphoma
  di: Joel Wight, et al.
  Pubblicazione: (2025)
• Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report
  di: Arina Martynchyk, et al.
  Pubblicazione: (2025)